We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Keytruda Gains Another Cancer Indication: Advanced Renal Cell Carcinoma
Keytruda Gains Another Cancer Indication: Advanced Renal Cell Carcinoma
The FDA has approved the combination of Merck’s Keytruda (pembrolizumab) and Eisai’s Lenvima (lenvatinib) for the first-line treatment of adult patients with advanced renal cell carcinoma, the companies announced late Wednesday.